Development of personalized treatments in lung cancer: Focusing on the EGFR mutations and beyond

Lung Cancer: Targets and Therapy

Volumn 4, Issue , 2013, Pages 43-53

  Suda, Kenichi ^a,b   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Acquired resistance; Adjuvant therapy; Epidermal growth factor receptor mutation; Molecular target; Personalized therapy; Predictive biomarkers

Indexed keywords

AFATINIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PEMETREXED; PLACEBO;

CANCER ADJUVANT THERAPY; CANCER RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; EGFR GENE; ENZYME STRUCTURE; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG CANCER; LUNG SURGERY; MUTATIONAL ANALYSIS; PARONYCHIA; PERSONALIZED MEDICINE; RASH; REVIEW; SIGNAL TRANSDUCTION; TOXIC HEPATITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84889805921     PISSN: None     EISSN: 11792728     Source Type: Journal    
DOI: 10.2147/LCTT.S49603     Document Type: Review

References (89)

1. Mitsudomi T, Morita S, Yatabe Y, etal; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121-128.
2. Maemondo M, Inoue A, Kobayashi K, etal; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.
3. Rosell R, Carcereny E, Gervais R, etal; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
4. Zhou C, Wu YL, Chen G, etal. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3study. Lancet Oncol. 2011;12(8):735-742.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-354.
6. Selvaggi G, Novello S, Torri V, etal. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15(1):28-32.
7. Giaccone G, Herbst RS, Manegold C, etal. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol. 2004;22(5):777-784.
8. Herbst RS, Prager D, Hermann R, etal; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892-5899.
9. Herbst RS, Giaccone G, Schiller JH, etal. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004;22(5):785-794.
10. Gatzemeier U, Pluzanska A, Szczesna A, etal. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25(12):1545-1552.
11. Thatcher N, Chang A, Parikh P, etal. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527-1537.
12. Lynch TJ, Bell DW, Sordella R, etal. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
13. Paez JG, Jänne PA, Lee JC, etal. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-1500.
14. Suda K, Tomizawa K, and Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010;29:49-60.
15. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98(12):1817-1824.
16. Fukuoka M, Wu YL, Thongprasert S, etal. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866-2874.
17. Yang JC-H, Schuler MH, Yamamoto N, etal. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. American Society of Clinical Oncology (ASCO) Annual '12 Meeting, Chicago, Illinois, June 1-5, 2012. J Clin Oncol. 2012;30(Suppl: abstr LBA7500).
18. Wu YL, Zhou C, Hu C, etal. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. American Society of Clinical Oncology (ASCO) Annual '13 Meeting, Chicago, Illinois, 31 May-4 June, 2013. J Clin Oncol. 2013;31(Suppl: abstr 8016).
19. Takano T, Fukui T, Ohe Y, etal. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26(34):5589-5595.
20. Suda K, Ito S, Mizuuchi H, Maehara Y, Yatabe Y, Mitsudomi T. EGFR tyrosine kinase inhibitors prolong overall survival in EGFR mutated non-small-cell lung cancer patients with postsurgical recurrence. J Can Res Updates. 2012;1(1):102-107.
21. Schiller JH, Harrington D, Belani CP, etal; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98.
22. Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med. 2005;352(20):2136; author reply 2136.
23. Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer. 2013;80(3):235-241.
24. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812-3821.
25. Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008;68(7):2106-2111.
26. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011;29(22):2972-2977.
27. Engelman JA, Mukohara T, Zejnullahu K, etal. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006;116(10):2695-2706.
28. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol. 2004;15(2):171-176.
29. Sos ML, Koker M, Weir BA, etal. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009;69(8):3256-3261.
30. Yano S, Yamada T, Takeuchi S, etal. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 2011;6(12):2011-2017.
31. Maheswaran S, Sequist LV, Nagrath S, etal. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-377.
32. Rosell R, Molina MA, Costa C, etal. Pretreatment EGFR T790M mutation and BRCA1mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011;17(5):1160-1168.
33. Su KY, Chen HY, Li KC, etal. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433-440.
34. Faber AC, Corcoran RB, Ebi H, etal. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011;1(4):352-365.
35. Ng KP, Hillmer AM, Chuah CT, etal. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18(4):521-528.
36. Nakagawa T, Takeuchi S, Yamada T, etal. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res. 2013;73(8):2428-2434.
37. Bivona TG, Hieronymus H, Parker J, etal. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011;471(7339):523-526.
38. Karachaliou N, Costa C, Gimenez-Capitan A, etal; Spanish Lung Cancer Group. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. J Thorac Oncol. 2013;8(3):295-300.
39. Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol. 2006;1(7):629-634.
40. Fujita Y, Suda K, Kimura H, etal. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol. 2012;7(11):1640-1644.
41. Rosell R, Molina MA, Taron M, etal. EGFR compound mutants discriminate survival on erlotinib in non-small-cell lung cancer (NSCLC) patients (p) in the EURTAC study. American Society of Clinical Oncology (ASCO) Annual '12 Meeting, Chicago, Illinois, 1-5 June, 2012. J Clin Oncol. 2012;30(Suppl: abstr 7522).
42. Lee JK, Shin JY, Kim S, etal. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. Epub April 4, 2013.
43. Jackman D, Pao W, Riely GJ, etal. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28(2):357-360.
44. Kobayashi S, Boggon TJ, Dayaram T, etal. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-792.
45. Pao W, Miller VA, Politi KA, etal. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.
46. Arcila ME, Oxnard GR, Nafa K, etal. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17(5):1169-1180.
47. Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol. 2009;4(1):1-4.
48. Engelman JA, Zejnullahu K, Mitsudomi T, etal. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-1043.
49. Bean J, Brennan C, Shih JY, etal. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104(52):20932-20937.
50. Yano S, Wang W, Li Q, etal. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68(22):9479-9487.
51. Suda K, Murakami I, Katayama T, etal. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010;16(22):5489-5498.
52. Garofalo M, Romano G, Di Leva G, etal. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011;18(1):74-82.
53. Sequist LV, Waltman BA, Dias-Santagata D, etal. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
54. Suda K, Mizuuchi H, Maehara Y, Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev. 2012;31(3-4):807-814.
55. Takezawa K, Pirazzoli V, Arcila ME, etal. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2(10):922-933.
56. Zhang Z, Lee JC, Lin L, etal. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44(8):852-860.
57. Ercan D, Xu C, Yanagita M, etal. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012; 2(10):934-947.
58. Ohashi K, Sequist LV, Arcila ME, etal. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012;109(31):E2127-E2133.
59. Tabara K, Kanda R, Sonoda K, etal. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PloS One. 2012;7(7):e41017.
60. Shien K, Toyooka S, Yamamoto H, etal. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013;73(10):3051-3061.
61. Yu HA, Arcila ME, Rekhtman N, etal. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240-2247.
62. Engelman JA, Zejnullahu K, Gale CM, etal. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2mutations that are resistant to gefitinib. Cancer Res. 2007;67(24):11924-11932.
63. Li D, Ambrogio L, Shimamura T, etal. BIBW2992, an irreversible EGFR/HER2inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702-4711.
64. Janne PA, Schellens JH, Engelman JA, etal. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol. 2008;26(Suppl: abstr 8027).
65. Miller VA, Hirsh V, Cadranel J, etal. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528-538.
66. Zhou W, Ercan D, Chen L, etal. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462:1070-1074.
67. Ohashi K, Suda K, Sun J, etal. CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance in vitro. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC., Philadelphia, April 6-10, 2013. 2101A.
68. Lee HJ, Schaefer G, Heffron TP, etal. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov. 2013;3(2):168-181.
69. Sequist LV, Soria JC, Gadgeel SM, etal. First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. American Society of Clinical Oncology (ASCO) Annual '13 Meeting, Chicago, Illinois, 31 May-4 June, 2013. J Clin Oncol. 2013;31(Suppl: abstr 2524).
70. Chmielecki J, Foo J, Oxnard GR, etal. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90):90ra59.
71. Das Thakur M, Salangsang F, Landman AS, etal. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494(7436):251-255.
72. Inoue A, Kobayashi K, Maemondo M, etal. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54-59.
73. Riely GJ, Kris MG, Zhao B, etal. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007;13(17):5150-5155.
74. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011;17(19):6298-6303.
75. AstraZeneca. A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS). Available from: http://clinicaltrials.gov/show/NCT01544179. NLM identifier: NCT01544179. Accessed July 17, 2013.
76. Regales L, Gong Y, Shen R, etal. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119(10):3000-3010.
77. Janjigian YY, Smit E, Horn L, etal. Activity of afatinib/cetuximab in patients with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance to EGFR inhibitors. European Society for Medical Oncology (ESMO) 2012 Congress Vienna, Austria, 28 September-2 October, 2012. Ann Oncol. 2012;23:abstr 12270.
78. Kobayashi N, Toyooka S, Soh J, etal. The anti-proliferative effect of heat shock protein 90inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer. 2012;75(2):161-166.
79. Shimamura T, Li D, Ji H, etal. Hsp90inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008;68(14):5827-5838.
80. Pignon JP, Tribodet H, Scagliotti GV, etal; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559.
81. Mitsudomi T, Suda K, Yatabe Y. Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol. 2013;10(4):235-244.
82. Goss GD. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. American Society of Clinical Oncology (ASCO) Annual '10 Meeting, Chicago, Illinois, 4-8 June, 2010. J Clin Oncol. 2010;28(Suppl: abstr LBA7005).
83. D'Angelo SP, Janjigian YY, Ahye N, etal. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012;7(12):1815-1822.
84. A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial) Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&ac tion=brows&recptno=R000007398&type=summary&language=E Identifier: UMIN000006252. Accessed July 24, 2013.
85. Intergroupe Francophone de Cancerologie Thoracique. TAilored Post-Surgical Therapy in Early Stage NSCLC (TASTE). Available from: http://clinicaltrials.gov/show/NCT00775385. NLM identifier: NCT00775385. Accessed July 24, 2013.
86. Mok TS, Wu YL, Thongprasert S, etal. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-957.
87. Han JY, Park K, Kim SW, etal. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122-1128.
88. Isobe K, Hata Y, Kaburaki K, etal. Clinical significance of BIM deletion polymorphism in non-small cell lung cancer with epidermal growth factor receptor mutation. American Society of Clinical Oncology (ASCO) Annual '13 Meeting, Chicago, Illinois, 31 May-4 June, 2013. J Clin Oncol. 2013;31(Suppl: abstr 11052).
89. Horiike A, Nishio M, Goto K, etal. A phase II study of erlotinib as first-line treatment in Japanese advanced NSCLC patients harboring EGFR mutations. European Society for Medical Oncology (ESMO) 2012 Congress Vienna, Austria, 28 September-2 October, 2012. Ann Oncol. 2012;23(Suppl 9):ix413; abstr 1260P.